What is a tolerance break?
A tolerance break is a planned, time-limited cessation of medicinal cannabis use, undertaken to reset cannabinoid receptors and restore sensitivity to treatment. It is sometimes referred to informally as a ‘t-break’.
Regular use of THC-containing cannabis medications can lead patients to develop a tolerance to the therapeutic benefits of their treatment, meaning they may no longer experience the same degree of relief at their established dose.1
A tolerance break helps counteract this by allowing the cannabinoid receptors in the patient’s body to rest and reset, enabling the patient to return to their existing dose — or potentially a lower one — to achieve their desired therapeutic outcomes.
Understanding cannabis tolerance
When prescribing medicinal cannabis, the goal is to identify the most appropriate treatment for each patient — including format, cannabinoid content, terpene profile, and dose — to achieve symptom relief while maintaining physiological homeostasis.
These variables differ between patients, and a regimen effective for one patient may not be appropriate for another given differences in symptom profile and physiology.
Patients may be prescribed CBD-only treatments, THC-only treatments, or combined formulations containing both CBD and THC alongside other minor cannabinoids such as CBG or CBN. The way these cannabinoids affect each patient and influence tolerance depends on how they interact with the patient’s endocannabinoid system (ECS) — the molecular system responsible for regulating immune response, intercellular communication, sleep, digestion, stress, and pain response, among other functions. The ECS comprises cannabinoid receptors, endogenous cannabinoids (endocannabinoids), and the enzymes responsible for their synthesis and degradation.
CBD tolerance
Cannabidiol (CBD) is one of the most abundant cannabinoids in the cannabis plant. Unlike THC, it does not produce intoxication. CBD has a narrow side-effect profile,2 is non-impairing,3 and interacts indirectly with the ECS, binding only weakly to cannabinoid receptors. This means there is limited risk of CBD causing ECS dysregulation or receptor flooding.
As a result, patients are generally able to maintain their therapeutic CBD dose without significant tolerance development, dose escalation, or unwanted side effects. Where CBD-only patients do take breaks, these may help maintain treatment effectiveness over time. The risk of withdrawal symptoms during a CBD break is very low.
THC tolerance
THC is a psychoactive, intoxicating cannabinoid that acts directly on the ECS4 by stimulating CB1 and CB2 receptors, producing changes in central nervous system (CNS) function. Its therapeutic applications include analgesia, antiemesis, appetite stimulation, sleep improvement, and anxiolysis. Because the ECS is responsible for maintaining physiological balance, THC’s effects are dose-dependent: appropriate dosing may support homeostasis, while excessive or prolonged use can cause dysregulation.
Research has demonstrated that regular users of THC-containing treatments develop tolerance to both the impairing and the therapeutic effects of the cannabinoid over time.1 Patients may begin to report that their established dose is no longer achieving the same level of symptom relief.
This tolerance is not a permanent state, but rather a temporary reduction in cannabinoid receptor sensitivity that fluctuates with patterns of use. Patients can reset their cannabinoid receptors, restore sensitivity, and maintain their dose within a clinically appropriate range by taking structured breaks from treatment.
Does tolerance indicate addiction?
Tolerance to a substance is often conflated with chemical dependence or addiction, but the two are not synonymous. Tolerance can develop with a range of substances, including prescription medications and alcohol, without constituting addiction.
Tolerance becomes a clinical concern when it occurs alongside signs of problematic use — such as consumption beyond the prescribed amount, risk-taking behaviour, or neglect of responsibilities — which may indicate a more serious pattern of dependence.
Medicinal cannabis carries a low to moderate risk of dependence, which is notably lower than that associated with alcohol, nicotine, and prescription opioids.5
Structured tolerance breaks can reduce the amount of THC required to achieve therapeutic benefit and may help mitigate the risk of dependence over time. For most patients, the risk of withdrawal symptoms during a tolerance break is low.
What happens to the body during a tolerance break?
Prolonged THC consumption can lead the CNS to downregulate cannabinoid receptors in an attempt to restore physiological balance. Continuous activation of ECS cannabinoid receptors by THC causes a reduction in receptor density and sensitivity — a process that becomes cumulative when cannabis use is resumed before receptors have fully upregulated following the previous exposure.
During a tolerance break, cannabinoid receptors are allowed to readjust and chemically rebalance, restoring the patient’s sensitivity to cannabis and enabling them to achieve therapeutic benefit at a lower — or at least non-escalating — dose.
What are the clinical benefits of tolerance breaks?
Where a patient has developed tolerance to their medicinal cannabis treatment, continued dose escalation carries the risk of overwhelming the endocannabinoid system. Because THC acts directly on cannabinoid receptors, excessive use can flood these receptors and lead to ECS dysregulation, potentially resulting in adverse effects including insomnia and heightened anxiety.
CBD interacts with opioid, dopamine, and serotonin receptors — contributing to its analgesic, anxiolytic, and antidepressant potential, as well as possible immunomodulatory effects. THC, by contrast, works more directly on cannabinoid receptors, making receptor management particularly important in long-term THC treatment.
Where a patient is repeatedly requesting dose increases, a structured tolerance break is preferable to ongoing escalation. This approach supports continued therapeutic utility of THC — including for pain, sleep, and anxiety — while reducing the risk of ECS dysfunction.
Key clinical rationale for recommending a tolerance break includes:
- Reduced risk of dose escalation and cumulative cannabinoid exposure
- Sustained therapeutic efficacy over the longer term
- Reduced risk of dependence
- Preservation of ECS receptor sensitivity
- Potential to reduce total medication required
How to identify when a patient may need a tolerance break
If a patient reports that their established dose is no longer providing the same level of relief, tolerance should be considered as a potential cause. Clinical indicators that may suggest a tolerance break is warranted include:
- Reduced analgesic or symptomatic efficacy at the established dose
- Unsanctioned or requested dose escalation
- Increased sleep disturbance despite treatment
- Worsening anxiety symptoms
- Reduced antiemetic efficacy
- Medication being consumed ahead of schedule
Where reduced treatment efficacy is attributable to tolerance, a structured break is appropriate. It is important to work with patients to develop a clear tolerance break plan — including timing, duration, symptom management strategies during the break, and a protocol for resuming treatment.
How long should a tolerance break be?
There is no universally established timeframe for tolerance breaks. It is generally accepted that a minimum of 48 hours is required to allow cannabinoid receptors to begin resetting. For long-term or heavy users seeking a more complete reset — including full THC clearance — breaks of several weeks to one month may be more appropriate to restore optimal ECS function.
As with all aspects of treatment, the appropriate duration of a tolerance break should be determined on an individual basis, taking into account the patient’s history, current regimen, clinical condition, and goals.
Supporting patients after a tolerance break
When a patient resumes treatment following a tolerance break, a new starting dose should be prescribed — typically equivalent to approximately half of the patient’s previous dose. This allows for careful upward titration to establish the patient’s new therapeutic threshold.
If the patient achieves satisfactory therapeutic outcomes at a dose equal to or lower than their original dose, the tolerance break can be considered effective.
In some cases, it may be beneficial to introduce a new medicinal cannabis formulation with a different cannabinoid ratio or terpene profile at the point of resumption. This can support receptor re-engagement and help ensure the patient continues to derive maximal benefit from their treatment.
References
- 1. Mason NL, et al. Reduced responsiveness of the reward system is associated with tolerance to cannabis impairment in chronic users. Addict Biol. 2021;26(1):e12870.
- 2. Blessing EM, et al. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015;12(4):825-36.
- 3. Arkell TR, et al. Medical cannabis and driving. Australian Journal of General Practice. 2021;50(6).
- 4. Alger BE. Getting high on the endocannabinoid system. Cerebrum. 2013;2013:14.
- 5. Nutt DJ, King LA, Phillips LD. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010;376(9752):1558-65.
- 6. Desai S, et al. A Systematic Review and Meta-Analysis on the Effects of Exercise on the Endocannabinoid System. Cannabis Cannabinoid Res. 2022;7(4):388-408.
- 7. Hill MN, et al. Functional interactions between stress and the endocannabinoid system: from synaptic signaling to behavioral output. J Neurosci. 2010;30(45):14980-6.
- 8. Pava MJ, Woodward JJ. A review of the interactions between alcohol and the endocannabinoid system. Alcohol. 2012;46(3):185-204.
